Novel Quadruplets and the Age of Immunotherapies in the Treatment of Newly Diagnosed Multiple Myeloma

Affiliations

Comment

Dickran Kazandjian et al. JAMA Oncol. 2022.

. 2022 Sep 1;8(9):1260-1262.

doi: 10.1001/jamaoncol.2022.2421.

¹ Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.

No abstract available

Comment on

Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
Derman BA, Kansagra A, Zonder J, Stefka AT, Grinblatt DL, Anderson LD Jr, Gurbuxani S, Narula S, Rayani S, Major A, Kin A, Jiang K, Karrison T, Jasielec J, Jakubowiak AJ. Derman BA, et al. JAMA Oncol. 2022 Sep 1;8(9):1278-1286. doi: 10.1001/jamaoncol.2022.2424. JAMA Oncol. 2022. PMID: 35862034 Free PMC article. Clinical Trial.